secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001823239-25-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai expects 2024 revenue near midpoint of $255M-$265M; President of Nucleic Acid Production departs
--------------------------------------------------------------------------------

- Preliminary unaudited 2024 revenue expected near midpoint of $255M-$265M guidance range.
- Andrew Burch, President of Nucleic Acid Production, position eliminated; last day Jan 16, 2025.
- CEO Trey Martin will assume direct responsibility for Nucleic Acid Production segment.
- Q4 and full year 2024 earnings release scheduled for Feb 25, 2025 after market close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/0001823239-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/mrvi-20250102.htm
  HTML page:      https://secwatch.observer/filing/0001823239-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer